Cellid, Co., Ltd.

KOSDAQ 299660.KQ

Cellid, Co., Ltd. Dividend Yield on January 14, 2025: 0.00%

Cellid, Co., Ltd. Dividend Yield is 0.00% on January 14, 2025, a 0.00% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Cellid, Co., Ltd. 52-week high Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
Cellid, Co., Ltd. 52-week low Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
Cellid, Co., Ltd. average Dividend Yield for the last 52 weeks is 0.00%.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

KOSDAQ: 299660.KQ

Cellid, Co., Ltd.

CEO	Yuil Kang Chang
IPO Date	Feb. 19, 2019
Location	South Korea
Headquarters	Building 142, Korea Seoul National University
Employees	64
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.

Key trends

Past 5 years